Cannassure Therapeutics Ltd reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was ILS 33.78 million compared to ILS 34.03 million a year ago. Net loss was ILS 5.47 million compared to ILS 16.52 million a year ago.

Basic loss per share from continuing operations was ILS 6.6 compared to ILS 20 a year ago. Diluted loss per share from continuing operations was ILS 6.6.